On-Demand CME Videos
Closing the Healthcare Gaps in the Management of Moderate-to-Severe Atopic Dermatitis (AD) With Biologics
About
This activity was recorded at the Fall Clinical Dermatology Conference 2023.
Closing the Healthcare Gaps in the Management of Moderate-to-Severe Atopic Dermatitis (AD) With Biologics
This activity is supported by an educational grant from Lilly.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 1, 2023
December 31, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss the burden of disease in patients with moderate-to-severe AD
Describe how biologics target the disease pathway for AD
Review the clinical trial data for biologics to treat moderate-to-severe AD
Discuss the safety profile of biologics and how to manage adverse effects
Intended Audience
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Peter Lio, MD
Clinical Assistant Professor of Dermatology Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen
Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel
has disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.